FinTrust Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

FinTrust Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-123	Closed	-$909	–	1352
2023 Q2	$909	Hold	123	–	–	﹤0.01%	1112
2023 Q1	$909	Hold	123	–	–	﹤0.01%	1105
2022 Q4	$909	Hold	123	–	–	﹤0.01%	1102
2022 Q3	$1K	Sell	123 -498	-80%	-$5.26K	﹤0.01%	1200
2022 Q2	$7K	Hold	621	–	–	﹤0.01%	986
2022 Q1	$7K	Sell	621 -104,268	-99%	-$1.37M	﹤0.01%	1024
2021 Q4	$1.65M	Sell	104,889 -1,093	-1%	-$19K	0.39%	59
2021 Q3	$1.82M	Buy	105,982 +4,335	+4%	+$75.9K	0.48%	50
2021 Q2	$2.19M	Buy	+101,647	New	+$1.82M	0.57%	43
2019 Q1	–	Sell	-1,000	Closed	-$26K	–	1348
2018 Q4	$26K	Buy	+1,000	New	+$23.5K	0.01%	537

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FinTrust Capital Advisors's VNDA Position: Q3 2023 in Review

FinTrust Capital Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 123 shares — an estimated $909 sold.

FinTrust Capital Advisors first reported a position in VNDA in Q4 2018 and held it in 10 quarters. The position peaked at $2.19M in Q2 2021. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

FinTrust Capital Advisors reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
FinTrust Capital Advisors sold 123 Vanda Pharmaceuticals shares in Q3 2023, an estimated $909.
FinTrust Capital Advisors first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 10 quarters.
FinTrust Capital Advisors's Vanda Pharmaceuticals position peaked at $2.19M in Q2 2021.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on FinTrust Capital Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.